These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 16507509)
1. Role of P-glycoprotein in the hepatic metabolism of tacrolimus. Jeong H; Chiou WL Xenobiotica; 2006 Jan; 36(1):1-13. PubMed ID: 16507509 [TBL] [Abstract][Full Text] [Related]
2. Disposition of tacrolimus in isolated perfused rat liver: influence of troleandomycin, cyclosporine, and gg918. Wu CY; Benet LZ Drug Metab Dispos; 2003 Nov; 31(11):1292-5. PubMed ID: 14570757 [TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo correlation of hepatic transporter effects on erythromycin metabolism: characterizing the importance of transporter-enzyme interplay. Lam JL; Okochi H; Huang Y; Benet LZ Drug Metab Dispos; 2006 Aug; 34(8):1336-44. PubMed ID: 16698890 [TBL] [Abstract][Full Text] [Related]
4. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients. Fukudo M; Yano I; Yoshimura A; Masuda S; Uesugi M; Hosohata K; Katsura T; Ogura Y; Oike F; Takada Y; Uemoto S; Inui K Pharmacogenet Genomics; 2008 May; 18(5):413-23. PubMed ID: 18408564 [TBL] [Abstract][Full Text] [Related]
5. Elevated blood concentrations of calcineurin inhibitors during diarrheal episode in pediatric liver transplant recipients: involvement of the suppression of intestinal cytochrome P450 3A and P-glycoprotein. Maezono S; Sugimoto K; Sakamoto K; Ohmori M; Hishikawa S; Mizuta K; Kawarasaki H; Watanabe Y; Fujimura A Pediatr Transplant; 2005 Jun; 9(3):315-23. PubMed ID: 15910387 [TBL] [Abstract][Full Text] [Related]
6. Effects of a potent and specific P-glycoprotein inhibitor on the blood-brain barrier distribution and antinociceptive effect of morphine in the rat. Letrent SP; Pollack GM; Brouwer KR; Brouwer KL Drug Metab Dispos; 1999 Jul; 27(7):827-34. PubMed ID: 10383928 [TBL] [Abstract][Full Text] [Related]
7. Preclinical pharmacokinetic properties of the P-glycoprotein inhibitor GF120918A (HCl salt of GF120918, 9,10-dihydro-5-methoxy-9-oxo-N-[4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]phenyl]-4-acridine-carboxamide) in the mouse, rat, dog, and monkey. Ward KW; Azzarano LM J Pharmacol Exp Ther; 2004 Aug; 310(2):703-9. PubMed ID: 15056727 [TBL] [Abstract][Full Text] [Related]
8. Effect of multidrug resistance modulators on the hepatobiliary disposition of doxorubicin in the isolated perfused rat liver. Booth CL; Brouwer KR; Brouwer KL Cancer Res; 1998 Aug; 58(16):3641-8. PubMed ID: 9721873 [TBL] [Abstract][Full Text] [Related]
9. Effect of hematocrit and albumin concentration on hepatic clearance of tacrolimus (FK506) during rabbit liver perfusion. Chow FS; Piekoszewski W; Jusko WJ Drug Metab Dispos; 1997 May; 25(5):610-6. PubMed ID: 9152601 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of the modulation of P-glycoprotein (P-gp) on the intraocular disposition of its substrate in rabbits. Senthilkumari S; Velpandian T; Biswas NR; Saxena R; Ghose S Curr Eye Res; 2008 Apr; 33(4):333-43. PubMed ID: 18398708 [TBL] [Abstract][Full Text] [Related]
11. Mechanistic understanding of the different effects of Wuzhi Tablet (Schisandra sphenanthera extract) on the absorption and first-pass intestinal and hepatic metabolism of Tacrolimus (FK506). Qin XL; Bi HC; Wang XD; Li JL; Wang Y; Xue XP; Chen X; Wang CX; Xu le J; Wang YT; Huang M Int J Pharm; 2010 Apr; 389(1-2):114-21. PubMed ID: 20097278 [TBL] [Abstract][Full Text] [Related]
12. Limited interaction between tacrolimus and P-glycoprotein in the rat small intestine. Saitoh H; Saikachi Y; Kobayashi M; Yamaguchi M; Oda M; Yuhki Y; Achiwa K; Tadano K; Takahashi Y; Aungst BJ Eur J Pharm Sci; 2006 May; 28(1-2):34-42. PubMed ID: 16457995 [TBL] [Abstract][Full Text] [Related]
13. P-glycoprotein-mediated in vitro biliary excretion in sandwich-cultured rat hepatocytes. Annaert PP; Turncliff RZ; Booth CL; Thakker DR; Brouwer KL Drug Metab Dispos; 2001 Oct; 29(10):1277-83. PubMed ID: 11560870 [TBL] [Abstract][Full Text] [Related]
14. Hepatic microsome studies are insufficient to characterize in vivo hepatic metabolic clearance and metabolic drug-drug interactions: studies of digoxin metabolism in primary rat hepatocytes versus microsomes. Lam JL; Benet LZ Drug Metab Dispos; 2004 Nov; 32(11):1311-6. PubMed ID: 15483198 [TBL] [Abstract][Full Text] [Related]
15. Impact of curcumin-induced changes in P-glycoprotein and CYP3A expression on the pharmacokinetics of peroral celiprolol and midazolam in rats. Zhang W; Tan TM; Lim LY Drug Metab Dispos; 2007 Jan; 35(1):110-5. PubMed ID: 17050652 [TBL] [Abstract][Full Text] [Related]
16. The site-specific transport and metabolism of tacrolimus in rat small intestine. Tamura S; Tokunaga Y; Ibuki R; Amidon GL; Sezaki H; Yamashita S J Pharmacol Exp Ther; 2003 Jul; 306(1):310-6. PubMed ID: 12676880 [TBL] [Abstract][Full Text] [Related]
17. Alteration of fexofenadine disposition in the rat isolated perfused liver following injection of bacterial lipopolysaccharide. Tong Y; Zhang R; Ngo SN; Davey AK Clin Exp Pharmacol Physiol; 2006 Aug; 33(8):685-9. PubMed ID: 16895540 [TBL] [Abstract][Full Text] [Related]
18. Cerebral uptake of mefloquine enantiomers with and without the P-gp inhibitor elacridar (GF1210918) in mice. Barraud de Lagerie S; Comets E; Gautrand C; Fernandez C; Auchere D; Singlas E; Mentre F; Gimenez F Br J Pharmacol; 2004 Apr; 141(7):1214-22. PubMed ID: 15023856 [TBL] [Abstract][Full Text] [Related]
19. Novel double coated nanocapsules for intestinal delivery and enhanced oral bioavailability of tacrolimus, a P-gp substrate drug. Nassar T; Rom A; Nyska A; Benita S J Control Release; 2009 Jan; 133(1):77-84. PubMed ID: 18822327 [TBL] [Abstract][Full Text] [Related]
20. Effect of telaprevir on the metabolism and hepatic uptake of tacrolimus (FK506). Oda K; Yamano K Biopharm Drug Dispos; 2014 Dec; 35(9):501-12. PubMed ID: 25059890 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]